Peter Attia hosts this Ask Me Anything episode of The Drive podcast, addressing one of the most requested topics: peptides. The discussion aims to provide a framework for evaluating peptides rather than promoting or dismissing them entirely.

The conversation covers what peptides are fundamentally - short chains of amino acids that include naturally occurring compounds like insulin and GLP-1. However, the focus shifts to gray market peptides popular in biohacking circles that lack FDA approval.

Attia establishes a systematic approach for evaluating any drug or peptide through key questions: mechanism of action, efficacy data, safety profile, risk-benefit analysis, and availability of approved alternatives. This framework will be applied to popular peptides including SS31, Melanotan 2, CJC 1295, and BPC 157.

Defining Peptides: From Natural Compounds to Gray Market Products

Peptides are short chains of amino acids, typically under 60-100 amino acids, that serve essential biological functions as signaling molecules, neurotransmitters, and transport facilitators.

Familiar peptide hormones include insulin, endorphins, and GLP-1, with insulin representing the most important therapeutic peptide discovered roughly 100 years ago for treating type 1 diabetes.

Gray market peptides are sold as 'research use only' to circumvent FDA approval requirements, despite being understood for human consumption in biohacking and wellness communities.

Framework for Evaluating Any Drug or Peptide

First question: Is there a viable mechanism of action with defined mechanistic steps, not vague theories like 'boosts energy production'?

Less than 3% of FDA-approved drugs lack known mechanisms of action, with rare exceptions including Tylenol, lithium, and mucinex - Peter

Additional critical questions include downstream effects in healthy individuals, safety data in humans, risk-benefit analysis, and availability of legitimate approved alternatives.

Antibiotics exemplify proper risk-benefit evaluation: 'Antibiotics have lots of side effects. Some of them can be really quite devastating. But we also know that they have really important intended downstream effects' - Peter

Four-Bucket Classification System for Peptides

Bucket 1: No compelling use case with no viable mechanism, lack of human data, or shifting goalposts for alleged benefits over time.

Bucket 2: Viable mechanism but never entered clinical trials, or trials were abandoned with no continued pharmaceutical interest.

Bucket 3: Viable mechanism, possibly in clinical trials or approved for other indications, with safety/efficacy data but no approved version for popular use.

Bucket 4: Essentially stolen FDA-approved drugs sold illegally via 'research purposes only' designation as exact replicas of approved medications.

Target Peptides for Detailed Analysis

Four peptides selected for comprehensive evaluation: SS31, Melanotan 2, CJC 1295, and BPC 157, chosen for their popularity and frequent patient inquiries.

Each peptide will be evaluated through the established framework examining clinical claims, evidence quality, risks, and practical considerations.

Additional database of approximately 20 other peptides with point-of-view assessments will be included in show notes for reference.

Resources Mentioned

use only' to avoid FDA approval requirements while being used by humans Peter Attia categorizes peptides into four buckets based on mechanism viability

at include familiar compounds like insulin, endorphins, and GLP-1 Gray market peptides are sold as 'research use only' to avoid FDA approval requirements while being used by humans Peter Attia categor

use only designation actually means

s. We're going to talk about how peptides are manufactured and sold in the gray market and what the research use only designation actually means, what third-party testing can evaluate and what it does

Get Ready for Work

ou as a listener. And it just took, I'm actually kind of afraid to ask how much time it took of our research team to help me get ready for this. So let's dive into it. Perfect. I think we got to start

STABLE

uire these things, in which their sale isn't technically illegal, but by marketing them for, quote, research use only, and I'm being very clear in that language, they're not approved for human use, bu

For Research Purposes Only Updated

old that are being touted as exact replicas of approved drugs, but they're being sold illegally via research purposes only. So we're going to talk through a handful of examples in a lot of detail to s

Ethics for Behavior Analysts

f course. Third, delivery of our premium newsletter, which is put together by our dedicated team of research analysts. This covers a wide range of topics related to longevity and provides much more de